3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ketosis
1
Insulin Resistance
1
Glioma
1
Glioblastoma
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
fludarabine
7
Cyclophosphamide
7
Nivolumab
6
Metformin
4
pembrolizumab
3
fludarabine phosphate
3
Radiotherapy
3
Melphalan
3
Ipilimumab
3
Interleukin-2
3
Injections
3
S 1 (combination)
2
Irinotecan
2
tremelimumab
1
selinexor
1
parsaclisib
1
olaparib
1
nabiximols
1
ivarmacitinib
1
durvalumab
1
defactinib
1
decitabine and cedazuridine drug combination
1
cedazuridine
1
carfilzomib
1
apatorsen
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
Topotecan
1
Rituximab
1
Radiosurgery
1
Radiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
OTHER_GOV
×
Diet, Carbohydrate-Restricted
×
Clear all
NCT02149459
2017-10-27
SMC 0712-13
Sheba Medical Center
Phase 1
Unknown
18 enrolled